Literature DB >> 10518304

Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease.

N Fausto1.   

Abstract

Hepatocytes have a remarkable proliferative capacity, but are quiescent in normal liver. Cell cycle activation in hepatocarcinogenesis can be directly triggered by overexpression of single and combinations of genes or be initiated indirectly by compensatory proliferation in response to liver injury. Work with transgenic and knockout mice indicate that regardless of the initiating cause, constitutive hepatocyte proliferation accompanied by genomic damage are essential factors for liver tumor development. The carcinogenic process is best described as a continuum that involves unregulated hyperplasia, dysplasia, and adenoma formation. The critical steps required for the transition from regulated to constitutive hepatocyte proliferation and the mechanisms of genomic damage in proliferating cells are being investigated. This knowledge should be directly applicable to studies of human liver tumorigenesis.

Entities:  

Mesh:

Year:  1999        PMID: 10518304     DOI: 10.1055/s-2007-1007114

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  35 in total

Review 1.  NF-κB and STAT3 - key players in liver inflammation and cancer.

Authors:  Guobin He; Michael Karin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

2.  mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

Authors:  Hala Elnakat Thomas; Carol A Mercer; Larissa S Carnevalli; Jongsun Park; Jesper B Andersen; Elizabeth A Conner; Kazuhiro Tanaka; Tomoo Matsutani; Akio Iwanami; Bruce J Aronow; Liu Manway; S Michel Maira; Snorri S Thorgeirsson; Paul S Mischel; George Thomas; Sara C Kozma
Journal:  Sci Transl Med       Date:  2012-04-25       Impact factor: 17.956

3.  FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.

Authors:  Xinle Wu; Hongfei Ge; Bryan Lemon; Steven Vonderfecht; Jennifer Weiszmann; Randy Hecht; Jamila Gupte; Todd Hager; Zhulun Wang; Richard Lindberg; Yang Li
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

4.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.

Authors:  Toshiharu Sakurai; Shin Maeda; Lufen Chang; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-28       Impact factor: 11.205

5.  Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma.

Authors:  Toshiharu Sakurai; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

6.  NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice.

Authors:  Shuang Liang; Hsiao-Yen Ma; Zhenyu Zhong; Debanjan Dhar; Xiao Liu; Jun Xu; Yukinori Koyama; Takahiro Nishio; Daniel Karin; Gabriel Karin; Ryan Mccubbin; Cuili Zhang; Ronglin Hu; Guizhi Yang; Li Chen; Souradipta Ganguly; Tian Lan; Michael Karin; Tatiana Kisseleva; David A Brenner
Journal:  Gastroenterology       Date:  2018-11-13       Impact factor: 22.682

7.  DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats.

Authors:  H-X Yan; H-P Wu; H-L Zhang; C Ashton; C Tong; J Wu; Q-J Qian; H-Y Wang; Q-L Ying
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

8.  NF-κB, JNK, and TLR Signaling Pathways in Hepatocarcinogenesis.

Authors:  Shin Maeda
Journal:  Gastroenterol Res Pract       Date:  2010-11-28       Impact factor: 2.260

9.  Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.

Authors:  Toshiharu Sakurai; Guobin He; Atsushi Matsuzawa; Guann-Yi Yu; Shin Maeda; Gary Hardiman; Michael Karin
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

Review 10.  Inflammation- and stress-related signaling pathways in hepatocarcinogenesis.

Authors:  Hayato Nakagawa; Shin Maeda
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.